Potential upside of 600%
Chart Setup (1‑Hr):
📈 Massive gap‑up on strong volume—ideal bull flag “pole.”
⚠️ Downward‑sloping consolidation channel = textbook bull flag.
🔥 Volume tapering during consolidation—often precedes sharp breakouts.
🚀 Approaching breakout near channel resistance (~$0.14), with 50‑ema & trendline support converging.
🎯 Technical Targets:
Near term: $0.20 (gap fill/resistance)
Measured move: ~$0.50 if breakout sustains
🧬 Fundamental Trigger – Clinical Readouts Imminent:
NuCana is expecting two key data updates in late 2025:
NUC‑7738 expansion trial (melanoma, post-PD‑1 failure) – top-line results due Q4 2025
finance.yahoo.com
NUC‑3373 Phase 1b/2 combination data (solid tumors + pembrolizumab) expected later this year
ir.nucana.com/static-files/e88b6c19-cedb-48c3-891d-aacfacb97ac4
These catalysts are on the horizon, and positive results could ignite a sharp pre-event ramp—especially in a low‑float biotech like NCNA.
🧠 Why This Matters
Bull flag + Fundamental setup = ideal trade structure: technical breakout, followed by a fundamental trigger.
Remember that this is a low float stock meaning less number of shares are available, thus any small positive news can result in a buying frenzy and a massive squeeze to the upside. Classic example is KALA (Kala Pharmaceuticals which rallied 800% in 2023
✅ Trade Plan
Action Target / Level
Entry On breakout above $0.14–0.15 with volume
Target First: $0.25 → Surge to $0.60 if catalyst is strong
Stop‑Loss Below channel support (~$0.11)
Bottom line:
NCNA is forming a textbook bull flag and is set up for a breakout ABOVE 0.2. With clinical trial results due SECOND HALF 2025, this trade could see significant upside before the headline.
Chart Setup (1‑Hr):
📈 Massive gap‑up on strong volume—ideal bull flag “pole.”
⚠️ Downward‑sloping consolidation channel = textbook bull flag.
🔥 Volume tapering during consolidation—often precedes sharp breakouts.
🚀 Approaching breakout near channel resistance (~$0.14), with 50‑ema & trendline support converging.
🎯 Technical Targets:
Near term: $0.20 (gap fill/resistance)
Measured move: ~$0.50 if breakout sustains
🧬 Fundamental Trigger – Clinical Readouts Imminent:
NuCana is expecting two key data updates in late 2025:
NUC‑7738 expansion trial (melanoma, post-PD‑1 failure) – top-line results due Q4 2025
finance.yahoo.com
NUC‑3373 Phase 1b/2 combination data (solid tumors + pembrolizumab) expected later this year
ir.nucana.com/static-files/e88b6c19-cedb-48c3-891d-aacfacb97ac4
These catalysts are on the horizon, and positive results could ignite a sharp pre-event ramp—especially in a low‑float biotech like NCNA.
🧠 Why This Matters
Bull flag + Fundamental setup = ideal trade structure: technical breakout, followed by a fundamental trigger.
Remember that this is a low float stock meaning less number of shares are available, thus any small positive news can result in a buying frenzy and a massive squeeze to the upside. Classic example is KALA (Kala Pharmaceuticals which rallied 800% in 2023
✅ Trade Plan
Action Target / Level
Entry On breakout above $0.14–0.15 with volume
Target First: $0.25 → Surge to $0.60 if catalyst is strong
Stop‑Loss Below channel support (~$0.11)
Bottom line:
NCNA is forming a textbook bull flag and is set up for a breakout ABOVE 0.2. With clinical trial results due SECOND HALF 2025, this trade could see significant upside before the headline.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.